Market news

Telix Pharmaceuticals Limited (NASDAQ:TLX) agreed on September 21 to acquire ITM Isotope Technologies Munich SE. The deal is worth up to $2.35 billion. Telix will pay $1.65 billion upfront, before cash and debt. A further $700 million follows if ITM’s lead drug wins approval and hits sales targets. Telix is paying mostly in its own […]

Telix Pharmaceuticals acquires ITM Isotope for $1.65B to create a radiopharmaceutical leader. Here is what investors need to know.

About This EventTelix Pharmaceuticals Limited (Nasdaq:TLX), a commercial-stage global radiopharmaceutical company, advancing precision diagnostics and targeted radionuclide therapies to improve outcomes for people with cancer, visits the Nasdaq MarketSite in Times Square.In honor of the occasion, Dr. Christian Behrenbruch, Managing Director & Group Chief Executive Officer rings the Closing Bell.

Telix Pharmaceuticals to buy Germany’s ITM Isotope in a $1.65B deal, boosting radiopharma scale and 2026 revenue outlook—read the details now.

Telix jumps on FDA approval of Pixclara for glioma FET-PET imaging. Read more here.

Detailed price information for Telix Pharm Ltd (TLPPF) from The Globe and Mail including charting and trades.

MELBOURNE, Australia and INDIANAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr. Christian Behrenbruch, Managing Director and Group CEO and Kevin Richardson, CEO, Precision Medicine will present at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference and at the H.C. Wainwright 28th Annual Global Investment Conference, both in New York, NY. Presentation details: Morgan Stanley 24th Annual Global Healthcare Co

Moby summary of Telix Pharmaceuticals Limited's Q2 2026 earnings call

MELBOURNE, Australia and INDIANAPOLIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City. Institutional investors and analysts are invited to register to attend the in-person session, which will feature a comprehensive overview of Telix's therapeutic and precision medicine pipeline, as well as key sci

Detailed price information for Telix Pharm Ltd (TLPPF) from The Globe and Mail including charting and trades.

The average of price targets set by Wall Street analysts indicates a potential upside of 86.2% in Telix Pharmaceuticals Limited (TLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today officially opens a multi-million dollar radiopharmaceutical research, manufacturing and treatment facility in Melbourne, expanding and strengthening Australia's capability in one of the world's fastest-growing areas of cancer diagnosis and treatment.

Detailed price information for Telix Pharm Ltd (TLPPF) from The Globe and Mail including charting and trades.